Royal DSM NV (Heerlen, the Netherlands, www.dsm.com) and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, www.crucell.com) have announced a nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com).
Royal DSM NV (Heerlen, the Netherlands, www.dsm.com) and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, www.crucell.com) have announced a nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com).
Sartorius will use Crucell’s key technology to evaluate MAbs produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and purification of recombinant MAbs. Crucell and Sartorius further agreed to expand their PER.C6 collaboration by sharing technology and data on antibody production. Financial details were not disclosed.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.